Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Aims & Scope

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is an exciting new initiative.

It represents a timely expansion of the journal Amyotrophic Lateral Sclerosis in response to the clinical, imaging pathological and genetic overlap between ALS and frontotemporal dementia.

The expanded journal provides outstanding coverage of research in a wide range of issues related to motor neuron diseases, especially ALS (Lou Gehrig’s disease) and cognitive decline associated with frontotemporal degeneration.

The journal also covers related disorders of the neuroaxis when relevant to these core conditions.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.8
2024	2.50

SJR (SCImago Journal Rank)

Year	Value
2024	0.957

Quartile

Year	Value
2024	Q1

Journal Rank

Year	Value
2024	5196

Journal Citation Indicator

Year	Value
2024	760

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Neuroscience, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria

  Citation: 756

  Authors: Michael J., Sharon, Laura H., Susan, Paula, Julie, Eneida, Angie, Michael, Tibor, Jeffrey, Vincenzo, Paul G, Martin R.

• Screening for cognition and behaviour changes in ALS

  Citation: 500

  Authors: Sharon, Judith, Elaine, Jennifer, Thomas H.

• A revision of the El Escorial criteria - 2015

  Citation: 394

  Authors: Albert, Vivian, Orla, Imaharu, John, Wim, Jeremy

• Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

  Citation: 291

  Authors: Koji, Yasuto, Gen, Shoji, Masashi, Manabu, Chikuma, Kazuoki, Takatomo, Makoto, Hiide

• Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS)

  Citation: 175

  Authors: Sabrina, Eric A., Alexandra, Alyssa, Judith, Amanda, Merit, Nazem

• Bulbar and speech motor assessment in ALS: Challenges and future directions

  Citation: 174

  Authors: Jordan R., Yana, Mili S., Jun, Gary L., Lori, Lorne, James D.

• Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

  Citation: 172

  Authors: Jesus S., Angela, Adriano, Conrado J., Delia, Maria, Saúl, Javier, Gabriel E., Monica, Andrés, Raul, Josep, Maria, Christian, Carlos, Nilo, Jessica, Alain, Jean-Pierre, Christian, Patrice, Vincent, Colin D., Olivier

• Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders

  Citation: 163

  Authors: Elaine, Judith, Jennifer, Shuna, Robert, Siddharthan, Thomas H., Sharon

• The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

  Citation: 151

  Authors: Barbara, Federica, Laura, Fabiana, Annalisa, Andrea, Alessia, Stefano, Daniela, Cinzia, Alberto, Federico, Antonia, Nicola, Sharon, Vincenzo

• Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis

  Citation: 143

  Authors: John, Stanley, Robert H., Richard, Benjamin, Lauren, Mary Kay, Christopher, Catherine, Jeffrey D., Leo, Hiroshi, Serge, Jeffrey, John Q., Leonard H., Steven

---